Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Themis Medicare Ltd Performance

Today's Low
206.60
arrowIcon
Today's High
213.20
52 Wk Low
132.61
arrowIcon
52 Wk High
263.85


Open

210.35

Traded Value (Cr)

64.59 L

Prev. Close

208.25

VWAP

209.25

Volume

19,826

Face Value

1

Themis Medicare Ltd Fundamentals

Market Cap
₹ 1,920 Cr
P/E Ratio (TTM)
42.41
P/B Ratio
5.81
Debt to Equity
0.26
ROE
14.07 %
EPS (TTM)
4.92
Dividend Yield
0.24%
Book Value
35.89

Click here to know more about Fundamentals

Themis Medicare Ltd Financials

Themis Medicare Ltd Financials

Themis Medicare Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 67.15 % 67.16 % 67.16 % 67.16 %
Retail 23.31 % 22.67 % 22.33 % 22.63 %
Others 9.51 % 10.16 % 10.46 % 10.17 %
FII 0.03 % 0.01 % 0.05 % 0.04 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

67.15%

Retail

23.31%

Others

9.51%

FII

0.03%

Mutual Funds

0.00%

Promoters

67.16%

Retail

22.67%

Others

10.16%

FII

0.01%

Mutual Funds

0.00%

Promoters

67.16%

Retail

22.33%

Others

10.46%

FII

0.05%

Mutual Funds

0.00%

Promoters

67.16%

Retail

22.63%

Others

10.17%

FII

0.04%

Mutual Funds

0.00%

Resistance and Support

₹215.38

PIVOT

resistance-arrow
Resistance
First Resistance₹217.567
Second Resistance₹220.883
Third Resistance₹223.067
support-arrow
Support
First Resistance₹212.067
Second Resistance₹209.883
Third Resistance₹206.567
RSI47.870
MACD-0.333
ADX15.084
CCI-68.288

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day19,82612,33962.24
Week34,91421,16060.68
1 Month44,59928,12364.40
6 Months24,73814,67659.33

About Themis Medicare Ltd

Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital. Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments. Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary. The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies. The Company introduced products like Cardiac and Muscular Relaxant during the year 2001-02. A wholly owned subsidiary of the Company, Themis Medicare Singapore Pte. Ltd., formed on 22nd May, 2002 in Singapore became operational during the year 2002-03. M/s. Artemis Biotech Ltd., a Group Company was merged with Themis Medicare Ltd. (the Parent Company) with effect from 1st April 2003. The Joint Venture Company, 'Richter Themis Medicare (India) Pvt. Ltd.' started manufacturing activities at its EOU unit at Vapi effective from March, 2006. The Company started operations of its new Injection Plant at Haridwar for tablets and gel formulation production in 2006-07. 'Themiseal', the Company's unique haemostatic and anti-microbial product was launched in the UK, Greece, Cyprus, Jordan, Romania and Indonesia. During the year 2010-11, a Private Ltd Subsidiary Company in the name and style of Themis Lifestyle Pvt. Ltd was incorporated on 3rd November, 2010 and another Public Ltd Subsidiary Company in the name and style of Artemis Biotech Ltd. was incorporated on 14th January, 2011. During FY 2016-17, HID-PUL KFT (Hungary), a Wholly Owned Subsidiary of the Company, ceased to be a subsidiary of the Company. 'Carpo Medical Limited' was incorporated as a Joint Venture Company in the United Kingdom in 2016-17.

Managing Director

Sachin D Patel

Founded

1969

NSE Symbol

THEMISMED

Themis Medicare Ltd Management

NameDesignation
Rajneesh AnandNon-Exec & Non-Independent Dir
VIJAY GOPI KISHAN AGARWALIndependent Non Exe. Director
Hari SubramaniamIndependent Non Exe. Director
Reena S PatelNon Executive Director
Sachin D PatelED / MD / CEO / Promoter
Dinesh S PatelChairman & Independent Directo
Manjul SandhuIndependent Non Exe. Director
Bhaskar Vemban IyerIndependent Non Exe. Director
Shishir DalalAdditional Director
Reena S PatelAlternate Director

Themis Medicare Ltd News

Themis Medicare announces board meeting date
On 14 May 2024
Themis Medicare consolidated net profit declines 44.63% in the December 2023 quarter
Sales decline 7.06% to Rs 82.51 crore
Themis Medicare announces board meeting date
On 10 February 2024
Themis Medicare launches novel Opioid Injectable Analgesic REMIFENTANIL
Themis Medicare consolidated net profit declines 36.33% in the September 2023 quarter
Sales rise 15.14% to Rs 104.78 crore
Themis Medicare to discuss results
On 4 November 2023
Themis Medicare fixes record date for stock split
Record date is 10 October 2023
Themis Medicare consolidated net profit rises 4.54% in the June 2023 quarter
Sales rise 2.34% to Rs 96.65 crore
Themis Medicare revises board meeting date
To 10 August 2023
Themis Medicare announces board meeting date
On 12 August 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,61,471 Cr
₹ 1,506.55
(0.80 %)
87.73
CIPLA₹ 1,08,154 Cr
₹ 1,339.55
(-1.42 %)
29.12
DIVISLAB₹ 1,00,705 Cr
₹ 3,793.50
(0.09 %)
73.80
ZYDUSLIFE₹ 98,827 Cr
₹ 982.15
(1.44 %)
36.80
DRREDDY₹ 98,773 Cr
₹ 5,921.00
(0.74 %)
22.73

Themis Medicare Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Themis Medicare Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Themis Medicare Ltd's share price is ₹209.00 as of May 10, 2024

Themis Medicare Ltd's P/E ratio is 42.41 times as of May 10, 2024.

Themis Medicare Ltd's most recent financial reports indicate a price-to-book ratio of 5.81, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Themis Medicare Ltd's market is 1,920 Cr as on May 10, 2024.

The current financial records of Themis Medicare Ltd show a 14.07% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Themis Medicare Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Themis Medicare Ltd's 52-week high and low as of May 10, 2024 are ₹213.2 and ₹206.6 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Themis Medicare Ltd stands at 67.15%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 0.01% to 0.03%.